Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 68071-3150

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 68071-3150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3150 3

68071 3150 3
This is a medicine labeled as Cyclobenzaprine HCI 10mg. It comes in a bottle of 30 tablets. Each tablet is round and yellow with "283" marked on one side and "Lot: 000000" on the other side. The medication is a muscle relaxant, and it is only to be used with a doctor's prescription. The label warns to keep the bottle out of the reach of children and to store it at a temperature of 68-77°F. The label also encourages patients to seek medical advice if they experience side effects and provides them with the contact number of the FDA.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
This is a chart showing the percentages of possible side effects experienced with the use of Cyclobenzaprine HCI Tablets at different dosages, as well as a placebo. The listed side effects are drowsiness, dry mouth, fatigue, and headache.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
This is a summary of the clinical studies and surveillance program conducted with Cyclobenzaprine HCl tablets of 10 mg. The studies found that 39% of patients experienced drowsiness, 2% reported dry mouth, and 1% experienced dizziness. The surveillance program revealed a 16% incidence of drowsiness, 7% of dry mouth, and 3% of dizziness.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.